HB 1601-FN-A - AS INTRODUCED
2024 SESSION
24-2336
10/05
HOUSE BILL 1601-FN-A
AN ACT relative to the prescription drug affordability board.
SPONSORS: Rep. Merchant, Sull. 6; Rep. Nagel, Belk. 6; Sen. Rosenwald, Dist 13; Sen. Abbas, Dist 22
COMMITTEE: Executive Departments and Administration
-----------------------------------------------------------------
ANALYSIS
This bill extends the executive director position of the prescription drug affordability board and modifies the procedure for approval of contracts.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
24-2336
10/05
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty Four
AN ACT relative to the prescription drug affordability board.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 Drug Affordability Board; Executive Director. Amend RSA 126-BB:2, VI to read as follows:
VI. The board shall be administratively attached to the department of health and human services. [For a limited time,] The board may employ an executive director, who shall be an unclassified employee. The executive director shall be appointed by and serve at the pleasure of the board. Said position shall be effective for no more than [2] 4 years following the date of hire of the individual first selected to fill the position. The board may also employ one contracted employee or more, dependent on the availability of funds.
2 Contract Approval. Amend RSA 126-BB:11 to read as follows:
126-BB:11 Competitive Bid Required. The contracts entered into by the board, including those for consulting services or personal contract services, shall be subject to the competitive bid process. Such contracts shall also be approved by the [fiscal committee of the general court, the] governor[,] and the executive council.
3 Effective Date. This act shall take effect July 1, 2024.
24-2336
12/12/23
HB 1601-FN-A- FISCAL NOTE
AS INTRODUCED
AN ACT relative to the prescription drug affordability board.
FISCAL IMPACT: [ X ] State [ ] County [ ] Local [ ] None
|
| |||||
Estimated State Impact - Increase / (Decrease) | ||||||
| FY 2024 | FY 2025 | FY 2026 | FY 2027 | ||
Revenue | $0 | $0 | $0 | $0 | ||
Revenue Fund(s) | None | |||||
Expenditures | $0 | $0 | $187,000 | $195,000 | ||
Funding Source(s) | General Fund | |||||
Appropriations | $0 | $0 | $0 | $0 | ||
Funding Source(s) | None | |||||
• Does this bill provide sufficient funding to cover estimated expenditures? [X] See Below • Does this bill authorize new positions to implement this bill? [X] No | ||||||
METHODOLOGY:
This bill extends by two years the expiration date for the position of executive director of the Prescription Drug Affordability Board. The executive director position has been determined by the Joint Committee on Employee Classification as an unclassified position at labor grade GG (annual salary range $87,373 through $121,751). Once benefits are included, for FY24 and FY25 the position has funding for $185,563 each year. The Department of Health and Human Services assumes that, once extended, the position will cost approximately $187,000 in FY26 and $195,000 in FY27.
AGENCIES CONTACTED:
Department of Health and Human Services